Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation (CONVINCE)

Pierrel Research

Status and phase: Terminated; Phase 3

Conditions: Allogeneic Stem Cell Transplantation

Treatments: Drug: Ganciclovir; Drug: Valganciclovir

Study type: Interventional

Funder types: Industry

Identifiers

NCT01185223

ML 22371

Details and patient eligibility

About

The objective of this study is to assess the efficacy and safety of oral valganciclovir versus intravenous ganciclovir in patients following allogenic stem cell transplantation.

Enrollment: 212 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient following allogeneic SCT
• Patient with a first episode of positive CMV-PCR (DNAemia) or pp65 antigenemia assay (antigenemia) up to 100 days after SCT
• Absolute neutrophil count (ANC) ≥1000 cells/µL on 2 consecutive follow-ups within 10 days before randomization
• Patient has a creatinine clearance of ≥25 mL/min (calculated by the Cockcroft-Gault formula, see Part I Section 6.1.2) with evidence of improving renal function,
• None or gastrointestinal graft-versus-host disease (GVHD) up to grade 2

Exclusion criteria

• Patient has a suspected or diagnosed CMV disease

• Patient has received syngeneic SCT

• Patient who received an investigational medicinal product (IMP) within the last 30 days prior to screening or who is simultaneously participating in another clinical study with an IMP

• Patient with a body weight <50 kg or >95 kg,

• Patient has received anti-CMV therapy within the past 30 days prior to screening (the use of acyclovir, valacyclovir, or famciclovir is permitted)

• Patient who has participated in this study before,

• Patient who shows a neutropenia, thrombocytopenia, or anemia within 10 days before or at the time point of randomization as following:

  • The ANC is <1000 cells/μL on 2 consecutive follow-ups, or
  • A platelet count of ≥25000/μL can not be achieved/maintained with platelet transfusions
  • A hemoglobin level of ≥8g/dL can not be achieved/maintained by red blood cell transfusions

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

212 participants in 2 patient groups

Valganciclovir

Other group

Treatment:

Drug: Valganciclovir

Ganciclovir

Active Comparator group

Treatment:

Drug: Ganciclovir